Literature DB >> 29056168

Cystic Fibrosis: A Risk Condition for Renal Disease.

Domenico Santoro1, Adele Postorino2, Cristina Lucanto3, Stefano Costa3, Simona Cristadoro3, Salvatore Pellegrino3, Giovanni Conti3, Michele Buemi2, Giuseppe Magazzù3, Guido Bellinghieri2.   

Abstract

OBJECTIVE: Cystic fibrosis (CF) is the most common autosomal recessive disease affecting the Caucasian population, with a birth incidence ranging between 1:2,500 and 1:1,800. It is caused by mutations in the CF transmembrane regulator gene which is localized on 7 chromosomes. Renal disease is reported as a relatively rare complication in adult patient with CF. We evaluated proteinuria and chronic renal failure (CRF) in a population of patients with CF.
METHODS: A retrospective study was carried out in a referral center for CF at University of Messina in Italy. We identified all patients with renal disease, characterized by proteinuria and/or CRF, during the period 2007 to 2012 and reviewed their medical records to assess influence on renal disease of genotype, number of pulmonary exacerbation, pancreatic insufficiency, pulmonary function, CF-related diabetes, and antibiotics courses.
RESULTS: From a population of 77 adult patients with CF, we identified 9 patients with proteinuria (11.7%), and 11 patients (14.28%) with CRF. Mean age was 35.6 (+5.1 standard deviation) years, 55% were female and 33% had diabetes mellitus. Renal biopsy was performed in 3 patients because of nephrotic syndrome in 1 patient and proteinuria with renal failure in the other 2 patients. Renal amyloidosis was disclosed in 2, whereas IgA nephropathy in 1 patient. The ΔF508 mutation in homozygosis was present in 44% of patients with proteinuria (vs. 27% of our CF population, relative risk 2.07), whereas genotype ΔF508/N1303K in 22%. ΔF508 allele mutation was present in 77.7% of proteinuric patients.
CONCLUSIONS: Our study shows a higher prevalence of renal disease in patients with CF, than was previously described. The main reason may be related to increased life expectancy because of better management. Moreover, patients with ΔF508 homozygosis had higher risk of proteinuria.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29056168     DOI: 10.1053/j.jrn.2017.05.006

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  6 in total

Review 1.  Secondary IgA nephropathy.

Authors:  Manish K Saha; Bruce A Julian; Jan Novak; Dana V Rizk
Journal:  Kidney Int       Date:  2018-05-24       Impact factor: 10.612

2.  Measurement of glomerular filtration rate in lung transplant recipients highlights a dramatic loss of renal function after transplantation.

Authors:  Nans Florens; Laurence Dubourg; Laurent Bitker; Emilie Kalbacher; François Philit; Jean François Mornex; François Parant; Fitsum Guebre-Egziabher; Laurent Juillard; Sandrine Lemoine
Journal:  Clin Kidney J       Date:  2020-05-09

3.  Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.

Authors:  Sergey K Zyryanov; Elena A Ushkalova; Elena I Kondratyeva; Olga I Butranova; Yulia A Kondakova
Journal:  Biomedicines       Date:  2022-05-02

4.  Renal Function in Patients with Cystic Fibrosis: A Single-Center Study.

Authors:  Marta Rachel; Sabina Galiniak; Marek Biesiadecki; Agnieszka Gala-Błądzińska
Journal:  Int J Environ Res Public Health       Date:  2022-04-29       Impact factor: 4.614

5.  Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis.

Authors:  Silvia Lai; Sandro Mazzaferro; Anna Paola Mitterhofer; Enea Bonci; Paolo Giangreco Marotta; Francesco Pelligra; Manuel Murciano; Camilla Celani; Patrizia Troiani; Giuseppe Cimino; Paolo Palange
Journal:  J Transl Med       Date:  2019-11-25       Impact factor: 5.531

Review 6.  Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications (Review).

Authors:  Tao Wei; Hongshu Sui; Yanping Su; Wanjing Cheng; Yunhua Liu; Zilin He; Qingchao Ji; Changlong Xu
Journal:  Mol Med Rep       Date:  2020-10-16       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.